We report a patient with primary hypothyroidism, who developed hepatocellular injury due to levothyroxine, synthetic thyroxine. A 63-year-old 
Introduction
Primary hypothyroidism, mainly caused by Hashimoto's thyroiditis, is mainly treated with replacement of thyroid hormones, especially oral administration of levothyroxine, i. e. synthetic thyroxine (T4) (1) . The use of levothyroxine for primary hypothyroidism has been well justified (2, 3) , since levothyroxine, peripherally metabolized into triiodothyronine (T3) through deiodination, can produce and maintain the proper amount of T3 required under physiologic control (1) . In general, levothyroxine is safe and well tolerated by patients, except for the possibility of developing osteoporosis in postmenopausal patients with excessive doses (1) . However, it has been known that administration of levothyroxine could cause liver injury, although scarcely reported (4) (5) (6) (Fig. 2a) . Focal necrosis and infiltration of eosinophils were observed within liver parenchyma (Fig. 2a) , without predominancy in centrilobular zones (Fig. 2b) . Taken together, we made a diagnosis as levothyroxine-induced liver injury, and changed replacement therapy from dried thyroid powder to liothyronine, synthetic T3, at the 17th hospital day.
While the serum value of ALT decreased after discontinuation of dried thyroid powder, total bilirubin as well as jaundice became exacerbated, as shown in Fig. 1 . Since the possibility that liothyronine also contributed to the liver injury was not excluded, liothyronine was discontinued at the 27th hospital day. Thereafter, liver enzymes and jaundice rapidly disappeared and the patient was discharged soon. (Fig. 1) Hi s t o p a t h o l o g i c a l s t u d i e s o f t h e b i o p s i e d s p e c i me n s o f t h e l i v e r d e mo n s t r a t e d ma r k e d  i n f i l t r a t i o n o f i n f l a mma t o r y c e l l s , c o n s i s t i n g o f c o n s i d e r a b l e e o s i n o p h i l s , wi t h i n a n d i n t h e v i c i n i t y  o f t h e e n l a r g e d a n d e d e ma t o u s p o r t a l t r a c t s . Mi l d p r o l i f e r a t i o n o f b i l e d u c t s a n d d e r a n g e me n t o f  c h o l a n g i o c y t e s we r e a l s o s e e n . F o c a l n e c r o s i s a n d i n f i l t r a t i o n o f e o s i n o p h i l s we r e o b s e r v e d wi t h i n  l i v e r p a r e n c h y ma ( a , h e ma t o x y l i n e o s i n s t a i n , × 2 0 0 ) , e v e n t h o u g h n e c r o s i s a n d d e g e n e r a t i o n o f h e  p a t o c y t e s wa s n o t r e ma r k a b l e i n c e n t r i l o b u l a r z o n e s ( b , s i l v e r s t a i n , × 4 0 0 ) .
Meanwhile, hypothyroidism had not been treated at all after discharge and symptoms including peripheral edema developed again. Hence we administered liothyronine as a replacement therapy, and no liver injury has noted subsequently
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Discussion
For the treatment of hypothyroidism, either primary or central, levothyroxine, synthetic T4, is primarily recommended (2, 3) due to several reasons. Orally administered levothyroxine is absorbed relatively slowly and equilibrates rapidly in its distribution volume, therefore avoiding large postabsorptive perturbations in free T4 levels (1) . In addition, levothyroxine is metabolized to its active form T3 peripherally and thus it is rational to supply the"prohormone", which is activated by physiologically regulated mechanisms (1) 
